EGFR and colonic neoplasm: In clinical practice, during our multidisciplinary team meetings, middle/low rectal cancer was noted to be refractory to anti-EGFR therapy to some extent, and the efficacy of this therapy for middle/low rectal cancer was below expectations compared to left-sided colon cancer.